Key Takeaways
CAR-T therapies have made inroads against various cancers, but an FDA label currently warns patients about a heightened risk for secondary cancers among people using the regimenA new analysis of data suggests that warning may not be warranted, with no evidence to confirm that CAR-T does, in fact, raise the dangerOther factors could explain the link, cancer researchers say
WEDNESDAY, Sept. 11, 2024 (HealthDay News) — Contrary to a warning placed on labels for CART-T cancer therapies, use of these treatments does not appear to boost the odds for a secondary cancer later, a new study shows.
Researchers at Memorial Sloan Kettering Cancer Center (MSKC) in New York City believe CAR-T may be safer in that regard than is now assumed, and warning labels may need to be revised.
The new data “do not suggest that there is an increased risk of second primary malignancies relative to other standard-of-care therapies,” …